Human Genome Sciences Inc. and SmithKline Beecham have restructured their three-year old agreement to allow other pharmaceutical companies to use the HGSI genomics database, give HGSI greater product development rights, and partially segment product development opportunities.

The addition of Schering-Plough as a collaborator, announced last week, as well as other recently announced agreements with other companies, may generate more than $140 million in revenues over the next five years. More than $90 million of that will go to HGSI and $50 million will go to SmithKline (SB).